BeStock  
Stocks › Biotechnology › BRVE

Braveheart Bio BRVE

US equityMarket cap rank #2736Biotechnology
$20.39 +$1.12 (+5.81%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $20.39 0.00%
Open$19.29
Prev close$19.27
Day range$18.83 – $21.16
Volume866.7K
Market cap$1.83B
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

BRVE at a glance

Braveheart Bio stock (BRVE) sits at $20.39, up 5.81% today. The business is worth $1.83B in the market, good for #2736 of 3753 on our coverage list.

Over the past 52 weeks it has traded between $16.70 and $32.00, so it sits 36.3% below the top of that range.

In the quarter ended Sep 2026 the company brought in $0.00 of revenue, and a net loss of $26.50M.

5 analysts follow the stock and the average call is "buy". The mean target, $45.50, sits 123.1% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Key statistics

Bid / Ask$16.88 / $24.88
Average price today$20.35
Volume866.7K
Turnover$17.64M
Turnover rate4.62%of shares outstanding
Volume ratio1.07vs. recent average pace
Day amplitude12.12%
Market cap$1.83B
Float market cap$382.31M
Shares outstanding18.75M
EPS (TTM)-$0.94
P/B3.68
Book value / share$5.54
Net profit (TTM)-$84.03M
Net assets$497.61M
30-day volatility69.7%annualized
Avg daily range (ATR)8.75%of price, 14 days
Max drawdown (1y)-41.9%-32.0% from 1y peak

Quote as of Nov 20, 2026 8:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

C
BeStock Grade

Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.

A
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

D
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

5 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$45.50+123.1% vs. current price
Consensus ratingBuy5 analysts covering
Morningstar fair value$26.85Price is below fair value

Wall Street’s average 12-month target is $45.50, 123.1% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $26.85, so shares trade 24.1% below that estimate. On earnings multiple, it sits in the 4th percentile of its own five-year valuation range (cheaper than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
+5.8%
1 week
+3.9%
1 month
-5.1%
3 months
-25.9%
Day range
$18.83$21.16
52-week range
$16.70$32.00

Technical signals

Full technicals →
Trend readStrong uptrend

4 bullish · 1 bearish of 5 signals

IndicatorValueSignal
Price vs 20-day average+1.1%Bullish
Price vs 50-day average-3.9%Bearish
RSI (14)50.6Bullish
MACD (12,26,9)-0.52Bullish
Bollinger band position54%Bullish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How BRVE ranks on BeStock

Market value#2724 of 3734
Closeness to 52-week high#2510 of 3724
Dollar volume today#2095 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

BRVE is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on BRVE.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on BRVE

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

BRVE stock: common questions

Where is BRVE trading right now?

$20.39 is the latest print for BRVE, a move of +5.81% against yesterday's close of $19.27. Today's low and high so far: $18.83 and $21.16.

What is BRVE worth in total?

Equity value comes to $1.83B at the current price. By that measure it is number 2736 of the 3753 names in our coverage.

Where does BRVE sit in its 52-week range?

The year's floor is $16.70 and the ceiling $32.00. Shares are 36.3% away from that ceiling.

Does BRVE send cash back through a dividend?

Our data shows no dividend paid by Braveheart Bio over the trailing twelve months.

Do Wall Street analysts like BRVE?

Of 5 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $45.50, with the most cautious at $40.00 and the most optimistic at $49.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on BRVE.

Sign in to join the discussion.

Scroll to Top